Dan Lü
Impact in
- Oncology top 5%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Immunology top 10%
- Immune Cell Function and Interaction
Papers in
- Oncology 24
- HER2/EGFR in Cancer Research 10
- CAR-T cell therapy research 9
- Immunology 19
- Immune Cell Function and Interaction 10
- T-cell and B-cell Immunology 8
- Co-authors
- Ie Ming Shih (2 shared papers)Peter Böhlen (5 shared papers)Morgan A. Marks (1 shared paper)Robert J. Kurman (1 shared paper)Malti Kshirsagar (1 shared paper)Russell Vang (1 shared paper)Anna Yemelyanova (1 shared paper)Zhenping Zhu (5 shared papers)
- Journals
- CPT Pharmacometrics & Systems Pharmacology (5 papers)Blood (4 papers)Frontiers in Immunology (4 papers)Cancer Research (4 papers)Cancer Chemotherapy and Pharmacology (3 papers)
- Partner nations
- United StatesChinaFrance
In The Last Decade
Dan Lü
66 papers receiving 2.3k citations
Dan Lü's Hit Papers
Peers
Comparison fields: 5 of 137
- Oncology 720
- Immunology 357
- Radiology, Nuclear Medicine and Imaging 360
- Reproductive Medicine 126
- Pathology and Forensic Medicine 258
Countries citing papers authored by Dan Lü
This map shows the geographic impact of Dan Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Lü more than expected).
Fields of papers citing papers by Dan Lü
This network shows the impact of papers produced by Dan Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Lü. The network helps show where Dan Lü may publish in the future.
Co-authors
The 25 scholars most cited alongside Dan Lü, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 67 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis Hit paper breakdown → | 2011 | 394 |
| 2 | 2002 | 315 | |
| 3 | 2003 | 158 | |
| 4 | 2003 | 131 | |
| 5 | 2001 | 122 | |
| 6 | 2019 | 93 | |
| 7 | 2020 | 73 | |
| 8 | 2007 | 72 | |
| 9 | 2016 | 67 | |
| 10 | 1999 | 61 | |
| 11 | 2000 | 59 | |
| 12 | 2010 | 46 | |
| 13 | 2011 | 45 | |
| 14 | 2021 | 41 | |
| 15 | 2016 | 41 | |
| 16 | 2010 | 39 | |
| 17 | 2022 | 36 | |
| 18 | 2009 | 32 | |
| 19 | 2017 | 32 | |
| 20 | 2019 | 31 |
About Dan Lü
Dan Lü is a scholar working on Oncology, Immunology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Pathology and Forensic Medicine, having authored 67 papers that have together received 2.4k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (18 papers), HER2/EGFR in Cancer Research (10 papers), Immune Cell Function and Interaction (10 papers), Lymphoma Diagnosis and Treatment (10 papers), CAR-T cell therapy research (9 papers), T-cell and B-cell Immunology (8 papers), Glycosylation and Glycoproteins Research (6 papers) and Angiogenesis and VEGF in Cancer (5 papers). The work is most often cited by research in Oncology (720 citations), Immunology (357 citations), Radiology, Nuclear Medicine and Imaging (360 citations), Reproductive Medicine (126 citations) and Pathology and Forensic Medicine (258 citations). Dan Lü has collaborated with scholars based in United States, China and France. Frequent co-authors include Ie Ming Shih, Peter Böhlen, Morgan A. Marks, Robert J. Kurman, Malti Kshirsagar, Russell Vang, Anna Yemelyanova, Zhenping Zhu, Xenia Jimenez and Larry Witte. Their work appears in journals such as CPT Pharmacometrics & Systems Pharmacology, Blood, Frontiers in Immunology, Cancer Research and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.